Cited by 133Fatty Acid Research and HealthCoronary Interventions and DiagnosticsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma

Nishio, Ryo, Shinke, Toshiro, Otake, Hiromasa, Nakagawa, Masayuki, Nagoshi, Ryoji, Inoue, Takumi, Kozuki, Amane, Hariki, Hirotoshi, Osue, Tsuyoshi, Taniguchi, Yu, Iwasaki, Masamichi, Hiranuma, Noritoshi, Konishi, Akihide, Kinutani, Hiroto, Shite, Junya, Hirata, Ken-ichi·2014·Atherosclerosis

DOI 10.1016/j.atherosclerosis.2014.02.025

Open this paper in CoChat — free account

Abstract

Background The addition of highly purified eicosapentaenoic acid (EPA) to statin therapy prevents cardiovascular events. However, the impact of this treatment on vulnerable plaques remains unclear. The aim of this study was to assess the impact of adding EPA to a standard statin therapy on vulnerable plaques by serial optical coherence tomography (OCT).Methods Forty-nine non-culprit thin-cap fibroatheroma (TCFA) lesions in 30 patients with untreated dyslipidemia were included. Patients were randomly assigned to EPA (1800 mg/day) + statin (23 TCFA, 15 patients) or statin only (26 TCFA, 15 patients) treatment. The statin (rosuvastatin) dose was adjusted to achieve a target low-density lipoprotein (LDL) level of <70 mg/dL. Post-percutaneous intervention and 9-month follow-up OCT were performed to evaluate morphological changes of TCFAs. The EPA/arachidonic acid (EPA/AA) ratio and pentraxin-3 (PTX3) levels were also evaluated.Results Despite similar follow-up LDL levels, the EPA + statin group had higher EPA/AA ratios and lower PTX3 levels than the statin group. OCT analysis showed that the EPA + statin group had a greater increase in fibrous-cap thickness, with a greater decrease in lipid arc and lipid length. Macrophage accumulation was less frequently detected in the EPA + statin group than in the statin group at follow-up. When the patients were categorized according to their follow-up PTX3 tertiles, fibrous-cap thickness showed significant increase, and the incidence of macrophages accumulation decreased with lower PTX3 levels.Conclusion The concomitant use of EPA and rosuvastatin may stabilize vulnerable plaques better than the statin alone, possibly by suppressing arterial inflammation.

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2014.02.025

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Universal Definition of Myocardial Infarction
Thygesen, K. A., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Mendis, S., Implementation Group: Lars C. Wallentin Coordinator (Sweden), F. F.-A. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,422
Lessons From Sudden Coronary Death: A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Untitled work
(1999) · PubMed · Cited by 2,062

Show all 29 references

Sorted by citations

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerlekar, N., Nicholls, S. J., & Layland, J. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 209
Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Watanabe, T., Ando, K., Daidoji, H., Otaki, Y., Sugawara, S., Matsui, M., Ikeno, E., Hirono, O., Miyawaki, H., Yashiro, Y., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.007 · Cited by 177
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes
Mason, R. P., Jacob, R. F., Shrivastava, S., Sherratt, S. C. R., & Chattopadhyay, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.10.002 · Cited by 179
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
OCT for the Identification of Vulnerable Plaque in Acute Coronary Syndrome
Sinclair, H., Bourantas, C. V., Bagnall, A. J., Mintz, G. S., & Kunadian, V. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.12.005 · Cited by 171
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01075-x · Cited by 156
EPA and DHA containing phospholipids have contrasting effects on membrane structure
Sherratt, S. C. R., Juliano, R. A., Copland, C., Bhatt, D. L., Libby, P., & Mason, R. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100106 · Cited by 92
Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study
Nosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.105 · Cited by 88
Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials
Ajabnoor, S. M., Thorpe, G., Abdelhamid, A. S., & Hooper, L. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02413-y · Cited by 87
Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound
Niki, T., Wakatsuki, T., Yamaguchi, K., Taketani, Y., Oeduka, H., Kusunose, K., Ise, T., Iwase, T., Yamada, H., Soeki, T., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-0813 · Cited by 83
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Brinton, E. A., & Mason, R. P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0415-8 · Cited by 83
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
Potential benefits of eicosapentaenoic acid on atherosclerotic plaques
Nelson, J. R., Wani, O. R., May, H. T., & Budoff, M. J. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.02.004 · Cited by 85
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
WEINTRAUB, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 74
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 69
In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches
Nusca, A., Viscusi, M. M., Piccirillo, F., Filippis, A. D., Nenna, A., Spadaccio, C., Nappi, F., Chello, C., Mangiacapra, F., Grigioni, F., et al. (2022) · Life · doi:10.3390/life12030393 · Cited by 68
“to prevent late stent failure confirm the potential relationship between lipid levels and NA [68].”
Background
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study
Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65
“Clinical trials using serial OCT imaging have demonstrated that statin therapy has a favorable effect on plaque, as evidenced by an increase in FCT and a reduction in the size of the lipid pool (47-53).”
BackgroundMethod
Do patients benefit from omega-3 fatty acids?
Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad188 · Cited by 75
“104 In contrast to these improvements with IPE, mixed EPA/DHA formulations have not shown significant changes in markers of plaque stability.”
Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities
van Veelen, A., van der Sangen, N. M. R., Delewi, R., Beijk, M. A. M., Henriques, J. P. S., & Claessen, B. E. P. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051361 · Cited by 52
Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system
Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 51
Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications
McClung, J. A., Levy, L., Garcia, V. G., Stec, D. E., Peterson, S. J., & Abraham, N. G. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107975 · Cited by 48
Omega-3 blood levels and stroke risk: a pooled and harmonized analysis of 183 291 participants from 29 prospective studies
O’Keefe, J. H., Tintle, N. L., Harris, W. S., O’Keefe, E. L., Sala-Vila, A., Attia, J., Garg, G. M., Hure, A., Bork, C. S., Schmidt, E. B., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.044281 · Cited by 46
“16 In a study of 188 patients awaiting carotid endarterectomy, those randomized to fish oil (providing 1.4 g of DHA+EPA per day versus placebo) before surgery had a lower prevalence of vulnerable fibrous caps, an increased thickness of fibrous caps, and reduced signs of inflammation within the…”
BackgroundInfluential
EPA’s pleiotropic mechanisms of action: a narrative review
Nelson, J. R., Budoff, M. J., Wani, O. R., Le, V. T., Patel, D. K., Nelson, A., & Nemiroff, R. L. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1921491 · Cited by 46
“pentraxin-3, a biomarker of cardiac and arterial inflammation produced by macrophages and vascular smooth muscle cells in the region of atherosclerotic plaque, causing fibrous cap thickening and stabilization [126,127].”
Background
DHA 12‐LOX‐derived oxylipins regulate platelet activation and thrombus formation through a PKA‐dependent signaling pathway
Yamaguchi, A. A., Stanger, L., Freedman, C. J., Standley, M. S., Hoang, T., Adili, R., Tsai, W., van Hoorebeke, C., Holman, T. R., & Holinstat, M. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15184 · Cited by 44
Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study
Yamano, T., Kubo, T., Shiono, Y., Shimamura, K., Orii, M., Tanimoto, T., Matsuo, Y., Ino, Y., Kitabata, H., Yamaguchi, T., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.25593 · Cited by 40
Self-citation
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid
Chapman, M. J., & Mason, R. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108237 · Cited by 41
A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2022) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102450 · Cited by 49
Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids
Burke, M. F., Burke, F. M., & Soffer, D. E. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0700-z · Cited by 40
Identification and treatment of the vulnerable coronary plaque
van Veelen, A., van der Sangen, N. M. R., Henriques, J. P. S., & Claessen, B. E. P. M. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2301039 · Cited by 42
Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography ― Review and Meta-Analysis ―
Ozaki, Y., García‐García, H. M., Beyene, S., Hideo‐Kajita, A., Kuku, K. O., Kolm, P., & Waksman, R. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-1376 · Cited by 37
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study
Kita, Y., Watanabe, M., Kamon, D., Ueda, T., Soeda, T., Okayama, S., Ishigami, K., Kawata, H., Horii, M., Inoue, F., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015593 · Cited by 36
Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
Giovanni, G. D., & Nicholls, S. J. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100366 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 39
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Intracoronary Imaging in the Detection of Vulnerable Plaques
Batty, J. A., Subba, S., Luke, P., Gigi, L. W. C., Sinclair, H., & Kunadian, V. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0705-1 · Cited by 34
Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Sekikawa, A. M., Cui, C., Sugiyama, D., Fabio, A., Harris, W. S., & Zhang, X. (2019) · Nutrients · doi:10.3390/nu11112599 · Cited by 38
“The four RCTs that recruited patients with CHD evaluated atherosclerosis in the coronary artery using various methods (coronary computed tomography angiography [17], intravascular ultrasound [19,20], and optical, coherence tomography [18]) (Table 2).”
BackgroundMethodInfluential
Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 45
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 32
Suppression of Wnt Signaling and Osteogenic Changes in Vascular Smooth Muscle Cells by Eicosapentaenoic Acid
Saito, Y., Nakamura, K., Miura, D., Yunoki, K., Miyoshi, T., Yoshida, M., Kawakita, N., Kimura, T., Kondo, M., Sarashina, T., et al. (2017) · Nutrients · doi:10.3390/nu9080858 · Cited by 28
“Evaluation using optical coherence tomography and intravascular ultrasound demonstrated that adding on EPA to statin did not change calcified plaque volume; however, it did stabilize the plaques of human coronary arteries [47,48].”
Background
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson, J. R., True, W. S., Le, V., & Mason, R. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1385365 · Cited by 27
“[38,43,45], lipid volume [45], and intima-media thickness [39– 41]; increases in fibrous-cap thickness [21,46,47] and fibrous volume [44]; and prevention of plaque progression [37].”
Background
Lipid-lowering Therapy and Coronary Plaque Regression
Ueki, Y., Itagaki, T., & Kuwahara, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22024 · Cited by 28
“…significantly increased FCT by OCT at 9 months compared with rosuvastatin alone (+54.8 μm vs. +23.5 μm, P ＜ 0.001) in 30 patients undergoing PCI 61) , while Kita et al. in 2020 reported that EPA or EPA+docosahexaenoic acid (DHA) therapy in addition to statin therapy did not significantly…”
BackgroundInfluential
Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease
Nagahara, Y., Motoyama, S., Sarai, M., Ito, H., Kawai, H., Takakuwa, Y., Miyagi, M., Shibata, D., Takahashi, H., Naruse, H., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.04.026 · Cited by 27
Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
Hilleman, D. E., & Smer, A. M. (2016) · PubMed · Cited by 26
Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study
Montarello, N. J., Singh, K., Sinhal, A. R., Wong, D. T. L., Alcock, R. F., Rajendran, S., Dautov, R. F., Barlis, P., Patel, S., Nidorf, S. M., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07240-9 · Cited by 26
Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaques Using Optical Coherence Tomography: A Systematic Review and Meta‐Analysis
Zheng, G., Chen, J., Lin, C.-Y., Huang, X., & Lin, J. (2015) · Journal of Interventional Cardiology · doi:10.1111/joic.12245 · Cited by 26
Membrane modulatory effects of omega-3 fatty acids: Analysis of molecular level interactions
Ayee, M. A. A., Bunker, B. C., & Groot, J. L. D. (2020) · Current topics in membranes · doi:10.1016/bs.ctm.2020.08.001 · Cited by 24
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 25
Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial
Kuroda, K., Otake, H., Shinohara, M., Kuroda, M., Tsuda, S., Toba, T., Nagano, Y., Toh, R., Ishida, T., Shinke, T., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-18-01073 · Cited by 22
“segments [3], and the lipid index was calculated by multiplying the mean lipid core arc by the lipid core”
MethodSelf-citation
Understanding why REDUCE-IT was positive – Mechanistic overview of eicosapentaenoic acid
Harris, W. S. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.008 · Cited by 21
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Gaba, P., Bhatt, D. L., Mason, R. P., Miller, M. J., Verma, S., Steg, P. G., & Boden, W. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.067 · Cited by 22
Anti-arrhythmic properties of non-antiarrhythmic medications
Williams, E. A., Russo, V., Ceraso, S., Gupta, D., & Barrett‐Jolley, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104762 · Cited by 20
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention
Trivedi, K., Le, V. T., & Nelson, J. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1783937 · Cited by 20
“001 [9] ● Decreased pentraxin-3: In patients with CAD treated with PCI, EPA added to statin therapy after 9 months reduced pentraxin 3 levels vs statin alone [47] ● Decreased Lp-PLA2: In ANCHOR, IPE 4 g/day decreased Lp-PLA2 by 19.”
Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression
Rivera, F. B., Cha, S. W., Varona, M. C., Co, E. M. F., Magalong, J. V., Aparece, J. P., Oliveira-Gomes, D. D., Kaur, G., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100645 · Cited by 20
Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA
Bittner, D. O., Goeller, M., Dey, D., Zopf, Y., Achenbach, S. S., & Marwan, M. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.10.006 · Cited by 18
New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 19
Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollution
Sherratt, S. C. R., Libby, P., Dawoud, H., Bhatt, D. L., Maliñski, T., & Mason, R. P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114629 · Cited by 17
Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging
Konishi, T., Sunaga, D., Funayama, N., Yamamoto, T., Murakami, H., Hotta, D., Nojima, M., & Tanaka, S. (2019) · Clinical Cardiology · doi:10.1002/clc.23185 · Cited by 17
“Second, EPA lowered the levels of pentraxin 3, an inflammatory marker associated with TCFA.33,34 Yamano et al. showed that EPA administration for 8 months significantly increased the FCT in OCT analysis for nonculprit plaques with a percent diameter stenosis of 30% to 70%.35 Although the mean minimum FCT was higher in…”
Background
Meta-Analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques
Fan, H., Zhou, J., & Yuan, Z. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.04.013 · Cited by 18
Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin
Otake, H., Sugizaki, Y., Toba, T., Nagano, Y., Tsukiyama, Y., Yanaka, K., Yamamoto, H., Nagasawa, A., Onishi, H., Takeshige, R., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.11.012 · Cited by 17
Self-citation
The Benefits of Omega-3 Fats for Stabilizing and Remodeling Atherosclerosis.
DiNicolantonio, J. J., & O’Keefe, J. H. (2020) · Europe PMC (PubMed Central) · Cited by 16
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s210149 · Cited by 14
Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction
Greene, S. J., Temporelli, P. L., Campia, U., Vaduganathan, M., Esposti, L. D., Buda, S., Veronesi, C., Butler, J., & Nodari, S. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.10.050 · Cited by 14
Impact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall
Giovanni, G. D., Kataoka, Y., Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.017 · Cited by 15
A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021
Iqbal, T., & Miller, M. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01527-x · Cited by 14
Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155161 · Cited by 14
Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study
Tani, S., Nagao, K., Yagi, T., Atsumi, W., & Hirayama, A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0195-y · Cited by 15
“Several studies to date have reported reduction of the plasma PTX3 level with uncombined statin treatment [9, 11, 12] and with combined statin plus EPA treatment [21]; however, there are few reports concerning the effect of addition of EPA to ongoing statin treatment on the”
Background
Optimization of coronary optical coherence tomography imaging using the attenuation-compensated technique: a validation study
Teo, J. C., Foin, N., Otsuka, F., Bulluck, H., Fam, J. M., Wong, P. E. H., Low, F. H., Leo, H. L., Mari, J. M., Joner, M., et al. (2016) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jew153 · Cited by 13
Low eicosapentaenoic acid to arachidonic acid ratio is associated with thin-cap fibroatheroma determined by optical coherence tomography
Wakabayashi, Y., Funayama, H., Ugata, Y., Taniguchi, Y., Hoshino, H., Ako, J., & Momomura, S. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.01.008 · Cited by 13
Self-citation
Assessing the Efficacy of Omega-3 Fatty Acids + Statins vs. Statins Only on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of 40,991 Patients
Irfan, A., Haider, S. H., Nasir, A., Larik, M. O., & Naz, T. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102245 · Cited by 12
Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention
Alfaddagh, A., Kapoor, K., Dardari, Z., Bhatt, D. L., Budoff, M. J., Nasir, K., Miller, M. J., Welty, F. K., Miedema, M. D., Shapiro, M. D., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1018 · Cited by 14
Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review
Borow, K. M., Mason, R. P., & Vijayaraghavan, K. (2017) · Cardiorenal Medicine · doi:10.1159/000479391 · Cited by 12
Effect of Intensive Lipid-Lowering Therapy on Coronary Plaque Stabilization Derived from Optical Coherence Tomography: a Meta-analysis and Meta-regression
Liu, S., Hou, J., Wan, J., Yang, Y., Wang, D., Liang, D., Wang, X., Zhou, P., & Wang, P. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07511-7 · Cited by 11
“Separate studies have evidenced that concurrent use of EPA and rosuvastatin induced a greater stabilization of vulnerable plaques than standalone statin treatment [16].”
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Effects of Eicosapentaenoic Acid on Arterial Calcification
Saito, Y., Nakamura, K., & Ito, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155455 · Cited by 11
Multi-modality intravascular imaging for guiding coronary intervention and assessing coronary atheroma: the Novasight Hybrid IVUS-OCT system
Bajaj, R., GARCIA-GARCIA, H. M., Courtney, B. K., RAMASAMY, A., TUFARO, V., Erdoğan, E., KHAN, A. H., ALVES, N., Rathod, K. S., Onuma, Y., et al. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05532-0 · Cited by 11
Management of Coronary Vulnerable Plaque With Medical Therapy or Local Preventive Percutaneous Coronary Intervention
Kim, H., Ahn, J., Kang, D., Lee, J., Choi, Y., Park, S., & Park, D. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.04.001 · Cited by 10
Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia
Doggrell, S. A. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1609942 · Cited by 11
Omega-3 fatty acids in the treatment of heart failure
Kelling, M., Dimza, M., Bartlett, A., Traktuev, D. O., Duarte, J. D., & Keeley, E. C. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102730 · Cited by 9
Effect of Eicosapentaenoic Acid/Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Noncontrast T1-weighted Imaging: The AQUAMARINE EPA/DHA Randomized Study
Nakao, K., Noguchi, T., Miura, H., Asaumi, Y., Morita, Y., Takeuchi, S., Matama, H., Sawada, K. S., Doi, T., Hosoda, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64063 · Cited by 9
“The number of serial examinations that had sufficient quality to be evaluated was 26, 21, and 24 in CMR and 24, 20, and 23 in CTA.”
Omega-3 Polyunsaturated Fatty Acids in Blood Pressure Control and Essential Hypertension
Colussi, G., Catena, C., Novello, M., & Sechi, L. A. (2016) · InTech eBooks · doi:10.5772/63501 · Cited by 9
“Finally, some studies have shown that omega-3 PUFA intake can enhance the beneficial effects of cardio-protective drugs such as statins and the acetylsalicylic acid [101–104].”
Background
Risk of Total Events With Icosapent Ethyl
Granger, C. B., Nelson, A. J., & Pagidipati, N. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.492 · Cited by 8
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial
Nakao, K., Noguchi, T., Asaumi, Y., Morita, Y., Kanaya, T., Fujino, M., Hosoda, H., Yoneda, S., Kawakami, S., Nagai, T., et al. (2018) · Trials · doi:10.1186/s13063-017-2353-1 · Cited by 7
Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment
Picard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8
Effects of Omega‐3 Fatty Acids Intake on Lipid Metabolism and Plaque Volume in Patients With Coronary Heart Disease: A Systematic Review and Dose–Response Meta‐Analysis of Randomized Clinical Trials
Zhang, C., Xie, Y., Zhou, J., Zhang, C., Xiang, Q., Zhong, Y., Xiao, J., Feng, J., Liao, B., Chen, X., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70372 · Cited by 8
“…outlined in Table 1 (Sacks et al. 1995; von Schacky et al. 1999; Johansen et al. 1999; Seierstad et al. 2005; Lee et al. 2006; Ishikawa et al. 2010; Nishio et al. 2014; Ahn et al. 2016; Niki et al. 2016; Tani et al. 2017, 2019, 2020; Watanabe et al. 2017; Alfaddagh et al. 2017; Samavat et al.…”
Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging
Abrahams, T., Fujino, M., Nelson, A. J., & Nicholls, S. J. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001080 · Cited by 7
EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis
Sheppard, J. P., Lakshmanan, S., Dahal, S., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2022) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2022.04.014 · Cited by 7
Inflammation in Atherosclerotic Cardiovascular Diseases: Biomarkers to Therapeutics in Clinical Settings
Kim, S., & Jang, A. Y. (2024) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2024.0014 · Cited by 8
The sequence of changes in intravascular imaging findings during lipid-lowering therapy and its implication
Fujimoto, D., Fuster, V., & Jang, I. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00664-8 · Cited by 6
“Concurrently, other OCT features of vulnerability, such as the presence and degree of accumulation of macrophages 38,45,50,51 , also undergo changes.”
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides
Kedia, A. W., & Lynch, E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1100086 · Cited by 6
Optical Coherence Tomography and Virtual-Histology Intravascular Ultrasound
Mintz, G. S. (2015) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.004045 · Cited by 6
The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
“(2014) [79] 30 CAD undergoing PCI 1800:0 Optical coherent tomography 9 months A greater increase in fibrous-cap thickness, with a greater decrease in lipid arc, lipid length and macrophage accumulation was detected in the EPA group”
Impact of pericoronary adipose tissue attenuation on clinical outcomes after percutaneous coronary intervention
Naniwa, S., Kawamori, H., Toba, T., Hiromasa, T., Sugizaki, Y., Sasaki, S., Fujii, H., Hamana, T., Osumi, Y., Yamamoto, T., et al. (2025) · EuroIntervention · doi:10.4244/eij-d-24-00971 · Cited by 5
Self-citation
Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis
Patti, G., Grisafi, L., Azzolina, D., Cumitini, L., D’Amario, D., & Mennuni, M. G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120433 · Cited by 5

Authors: Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., Iwasaki, M., Hiranuma, N., Konishi, A., Kinutani, H., Shite, J., & Hirata, K.-I.
Affiliations: Kobe University (JP)
ORCID: Shinke, Toshiro
Otake, Hiromasa
Nakagawa, Masayuki
Nagoshi, Ryoji
Inoue, Takumi
Kozuki, Amane
Osue, Tsuyoshi
Taniguchi, Yu
Iwasaki, Masamichi
Konishi, Akihide
Kinutani, Hiroto
Shite, Junya
Hirata, Ken-ichi
Venue: Atherosclerosis
Publisher: Elsevier BV
Published: 2014-05
Volume: 234
Issue: 1
Pages: 114-119
ISSN: 0021-9150 (ISSN-L)
DOI: 10.1016/j.atherosclerosis.2014.02.025
OpenAlex: W2048776656
Cited by: 133
References: 29
Citations by year: 2026: 2 · 2025: 10 · 2024: 9 · 2023: 16 · 2022: 20 · 2021: 14 · 2020: 14 · 2019: 13 · 2018: 3 · 2017: 9 · 2016: 11 · 2015: 10 · 2014: 2
FWCI: 9.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Atherosclerosis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: eicosapentaenoic acid, statin therapy, rosuvastatin, thin-cap fibroatheroma, coronary artery disease, pentraxin 3, fibrous cap thickness, lipid arc, macrophage accumulation, arterial inflammation, dyslipidemia, percutaneous coronary intervention
MeSH terms: Coronary Artery Disease, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Eicosapentaenoic Acid, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Tomography, Optical Coherence, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks